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Dear Editor,
We read with great interest the paper entitled ‘‘Immediate
suppression of seizure clusters by corticosteroids in PCDH19
female epilepsy’’ by Higurashi et al. [1].
Clusters of febrile and afebrile seizures, mainly focal motor or
hypomotor with affective symptoms, are typical of PCDH19 female
epilepsy (PCDH19-FE) [2]. After ﬁrst reporting on the excellent
efﬁcacy of corticosteroids in acute cluster termination in oneFig. 1. EEG ﬁndings in our patient. EEG in the acute encephalopathic phase, before IV
steroids administration: diffuse unreactive delta background activity,
predominating over the fronto-centro-temporal regions (A). Follow-up awake
EEG after 2 weeks: symmetrical posterior alpha activity without epileptiform
discharges (B).
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1059-1311/ 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights repatient with PCDH19-FE in 2013 [3], in this paper the authors
propose inﬂammatory processes causing functional breakdown of
blood brain barrier as a possible patophysiological mechanism
underlying epilepsy in PCDH19-FE [1]. This hypothesis would
justify the efﬁcacy of corticosteroids as an additional treatment
option in the acute setting.
We recently admitted an 8-year-old patient with PCDH-19-FE
harbouring a frameshift mutation pLeu807Profs*6 in heterozygous
duplication c.2406_2419 dup, who presented with recurrence of an
afebrile cluster of focal clonic and generalized tonic seizures.
Interictal EEG showed diffuse unreactive delta background
activity, maximal over the fronto-centro-temporal regions of both
hemispheres (Fig. 1A). At the time of admission she was on valproic
acid monotherapy.
Clinically, a predominantly lethargic status was only shortly
interrupted by wakefulness periods in which she was apathetic
and showed no verbal response.
As the clinical picture was in keeping with an acute epileptic
encephalopathy, we administered 20 mg/kg/day intravenous
methyl-prednisolone for 3 days, followed by oral deﬂazacort for
2 weeks, obtaining almost immediate seizure cessation (after the
ﬁrst infusion), while vigilance and social interaction recovered
within 2 days. After 6 days of therapy, speech function reverted to
the premorbid state. Restoration of posterior alpha activity on
awake EEG was observed within 2 weeks (Fig. 1B).
We think that our observation further supports acute treatment
with corticosteroids in patients with PCDH19-FE, and is in line with
recent investigations providing evidence of a potential scientiﬁc
rationale for their use. Dysregulation in the expression of aldo–
keto reductase 1C1-3 (AKR1C1-3) genes (encoding for steroid
hormone metabolizing enzymes) in skin ﬁbroblasts and reduced
blood levels of allopregnanolone (a GABA-R modulator showing
anticonvulsant effects) have been demonstrated in patients with
PCDH19-FE [4].
While research studies are warranted to reach better insight
into the pathopysiological mechanisms underlying efﬁcacy of
steroids in PCDH19-FE, we think that clinical descriptions can
signiﬁcantly add to the current knowledge regarding the clinical
relevance of this treatment approach.
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